DSMFF Stock Chart & Stats
$76.86
--
Market closed
$76.86
--
Day’s Range― - ―
52-Week Range$61.05 - $108.14
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$22.76B
Enterprise Value$22.04B
Total Cash (Recent Filing)$1.90B
Total Debt (Recent Filing)$5.28B
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Jul 30, 2026EPS Estimate
1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.16
Shares Outstanding253,626,950
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.98
Price to Sales (P/S)1.97
P/FCF Ratio28.57
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.44
Enterprise Value/Gross Profit5.87
Enterprise Value/Ebitda12.13
Forecast
1Y Price Target
$90.54Price Target Upside17.80% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)4.02
Revenue Forecast (FY)$10.48B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthManageable leverage and sizable equity provide a durable capital cushion that supports investment, R&D and potential M&A. A contained balance-sheet risk profile lowers refinancing stress during cycles and preserves strategic flexibility over the next several quarters.
Positive Cash GenerationSustained positive operating and free cash flow support ongoing operations, capex and shareholder distributions without relying solely on external financing. Even with recent weakening, continued positive cash generation underpins resilience and funds organic growth over the medium term.
Diversified B2B Ingredient PortfolioA broad portfolio across perfumery, taste, texture and nutrition plus embedded services builds recurring, stickier B2B relationships. Co-creation, formulation support and regulatory assistance raise customer switching costs and support sustained demand and pricing power across cycles.
Bears Say
Volatile ProfitabilityA swing to a sizable net loss signals earnings instability and one-off or structural cost pressures. Persistent volatility weakens earnings predictability, may force margin corrective actions, and can impair reinvestment capacity and dividend reliability over the medium term.
Sharp Revenue DeclineA roughly 29% revenue contraction indicates material demand or volume loss in core segments. Reduced scale erodes pricing leverage and fixed-cost absorption, pressuring margins and return on invested capital unless revenue recovery or strategic restructuring occurs.
Weakening Cash ConversionDeclining free cash flow and inconsistent cash conversion versus reported earnings reduce the firm's cushion for capex, working capital and dividends. This trend increases sensitivity to shocks and may necessitate cuts to discretionary spending or higher external financing over coming quarters.
DSM-Firmenich AG News
DSMFF FAQ
What was DSM-Firmenich AG’s price range in the past 12 months?
DSM-Firmenich AG lowest stock price was $61.05 and its highest was $108.14 in the past 12 months.
What is DSM-Firmenich AG’s market cap?
DSM-Firmenich AG’s market cap is $22.76B.
When is DSM-Firmenich AG’s upcoming earnings report date?
DSM-Firmenich AG’s upcoming earnings report date is Jul 30, 2026 which is in 22 days.
How were DSM-Firmenich AG’s earnings last quarter?
DSM-Firmenich AG released its earnings results on Feb 12, 2026. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $1.172 by -$0.432.
Is DSM-Firmenich AG overvalued?
According to Wall Street analysts DSM-Firmenich AG’s price is currently Undervalued.
Does DSM-Firmenich AG pay dividends?
DSM-Firmenich AG does not currently pay dividends.
What is DSM-Firmenich AG’s EPS estimate?
DSM-Firmenich AG’s EPS estimate is 1.02.
How many shares outstanding does DSM-Firmenich AG have?
DSM-Firmenich AG has 253,626,950 shares outstanding.
What happened to DSM-Firmenich AG’s price movement after its last earnings report?
DSM-Firmenich AG reported an EPS of $0.74 in its last earnings report, missing expectations of $1.172. Following the earnings report the stock price went down -8.286%.
Which hedge fund is a major shareholder of DSM-Firmenich AG?
Currently, no hedge funds are holding shares in DSMFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. The Animal Nutrition & Health segment offers animal proteins, vitamins, performance solutions, and data-driven precision services. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.
DSMFF Stock 12 Month Forecast
Average Price Target
$90.54
▲(17.80% Upside)
Ownership Overview
―
Insiders
11.61% Mutual Funds
0.18% Other Institutional Investors
77.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---